Drug Trial Radar · NCT02014376
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
Last checked: Nov 19, 2026Latest source record: Jan 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jan 6, 2014
Primary completion
Jun 24, 2014
Study completion Jun 24, 2014
Sponsor
- Lead sponsor
- Scioderm, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Amicus Therapeutics
- First posted
- Dec 18, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).
Conditions
- Epidermolysis Bullosa
Interventions
SD-101 dermal cream (3%)Drug
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
SD-101 Dermal Cream (6%)Drug
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Vehicle (SD-101 0%)Drug
A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With Documented Complete Closure Of The Target Wound Within 1 Month After Initiation Of TreatmentTime frame: Baseline to 1 Month
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Palo Alto, California
Site not named
Chicago, Illinois
Site not named
St Louis, Missouri
Site not named
Hackensack, New Jersey
Site not named
Chapel Hill, North Carolina
Site not named
San Antonio, Texas
Site not named
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.